Skip to main
BDX
BDX logo

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson's strong financial performance in FQ3'25, with Medical Surgical Systems (MMS) sales reaching $888 million, reflects a year-over-year growth of 5.3%, driven by robust demand for Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business has shown consistent annual growth exceeding 6% since the launch of the BD 2025 initiative, alongside improving margins, indicating a positive trend in operational efficiency. Furthermore, the Molecular Diagnostics Solutions (MDS) segment achieved FY24 sales of $4.43 billion, representing a 3.2% increase year-over-year, underscoring the company's diversified revenue streams and resilience in the healthcare market.

Bears say

Becton Dickinson's sales in FQ3'25 showed a decline of 1.1% year-over-year, indicating challenges in key sectors, particularly within Biosciences and Diagnostic Solutions. The company's organic revenue growth outlook has been lowered multiple times, now reflecting a range of 3.0-3.5%, which is significantly reduced from earlier projections. Additionally, headwinds such as volume-based procurement pressures in China and reduced demand due to government research funding cuts contribute to the negative outlook for the company's financial performance.

BDX has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 7 analysts, BDX has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.